(Q37860201)

24 August 2017

1 reference

title

Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy (English)

1 reference

24 August 2017

main subject

arterial hypertension

0 references

1

Jean-Luc Vachiéry

1 reference

24 August 2017

language of work or name

English

0 references

publication date

29 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

28

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

251-269

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0005-5

24 August 2017

exact match

0 references

cites work

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Novel approaches to treat experimental pulmonary arterial hypertension: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Treprostinil for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Long-term therapy with inhaled iloprost in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Management of severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Inhaled prostanoids in the therapy of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

The Role of PPARgamma in pulmonary vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

PPARgamma and the pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Revisiting the rosiglitazone story--lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Management of pulmonary arterial hypertension with a focus on combination therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Emerging therapies for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Novel approaches to the pharmacotherapy of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0005-5

10.1007/S12325-011-0005-5

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference